期刊
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 95, 期 11, 页码 E363-E367出版社
ENDOCRINE SOC
DOI: 10.1210/jc.2010-0511
关键词
-
资金
- Novo Nordisk (The Netherlands)
- Center for Human and Clinical Genetics
- Department of Endocrinology
- Metabolic Diseases (Leiden, The Netherlands)
Context: Homozygous IGF1 deletions or mutations lead to severe short stature, deafness, microcephaly, and mental retardation. Heterozygosity for an IGF-1 defect may modestly decrease height and head circumference. Objective: The objective of the study was to investigate the clinical features of heterozygous carriers of a novel mutation in the IGF1 gene in comparison with noncarriers in a short family and to establish the effect of human GH treatment. Subjects: Two children, their mother, and their maternal grandfather carried the mutation and were compared with two relatives who were noncarriers. Results: The two index cases had severe short stature (height SD score -4.1 and -4.6), microcephaly, and low IGF-1 levels. Sequencing of IGF1 revealed a heterozygous duplication of four nucleotides, resulting in a frame shift and a premature termination codon. The mother and maternal grandfather had the same IGF1 mutation. Adult height (corrected for shrinking and secular trend) and head circumference SD score of carriers of the paternally transmitted mutation was -2.5 and -1.8, in comparison with -1.6 and 0.3 in noncarriers, respectively. After 2yr of GH treatment, both index cases exhibited increased growth. Conclusions: Heterozygosity for this novel IGF1 mutation in children born from a mother with the same mutation, presumably in combination with other genetic factors for short stature, leads to severe short stature, which can be successfully treated with GH. (J Clin Endocrinol Metab 95: E363-E367, 2010)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据